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Background:Glomerulopathy is a group of diseases that affect mainly young adults. Endothelial dysfunction, ath-
erosclerosis, and increased cardiac mortality can complicate the evolution of such patients. However, there is no
study evaluating endothelial glycocalyx in this pathology.
Methods: This cross-sectional study included 49 patients with untreated primary nephrotic syndrome that were
otherwise healthy. In addition to routine laboratorymeasurements, syndecan-1, intercellular adhesionmolecule-
1 (ICAM-1), and e-selectin were measured. Moreover, ﬂow-mediated dilation (FMD) was used as the main en-
dothelial function surrogate.
Results: Of the 49 patients with nephrotic syndrome, 25 (51.0%) were females. The mean age of patients was
39.0 ± 12.1 y. FMD was reduced in nephrotic patients in comparison with controls (3.7 ± 1.7 vs. 6.6 ± 1.1%,
p b 0.001). Nephrotic patients had higher levels of ICAM-1 (616.6 ± 219.7 vs. 356.9 ± 102.0 ng/ml, p b 0.001)
and syndecan-1 (180.3± 64.1 vs. 28.2 ± 9.8 ng/ml, p b 0.001). No signiﬁcant difference was observed regarding
e-selectin (129.9± 54.2 vs. 120.2± 61.5 ng/ml, p= 0.489). After adjusting for age and glomerularﬁltration rate,
syndecan-1 was signiﬁcantly associated with 24-h urinary protein excretion, LDL-cholesterol, HDL-cholesterol,
and triglycerides. While age, LDL-cholesterol, and 24-h urinary protein excretion were associated with FMD in
the multivariate analysis, when syndecan-1, ICAM-1, and e-selectin were added to the model, only syndecan-1
was independently associated with FMD.
Conclusions: We demonstrated that syndecan-1, a marker of endothelial glycocalyx damage, is increased in pa-
tients with nephrotic syndrome and near-normal renal function. Moreover, we determined its association with
nephrotic syndrome features and suggest it can have a role in the endothelial dysfunction of these patients.© 2015 Elsevier B.V. All rights reserved.1. Introduction
Glomerulopathy is a group of diseases that affect mainly young
adults between 20 and 40 y. Patients with nephrotic syndrome general-
ly present with important edema, lipid alterations, hypoalbuminemia,
and possible loss of renal function [1]. The primary alteration in ne-
phrotic syndrome is a loss of the glomerularﬁltration barrier (consisting
of glomerular endothelium, glomerular basement membrane, and
podocytes). One major damaged component of ﬁltration barrier in ne-
phrotic syndrome is the podocyte. Podocytes are highly differentiated
epithelial cells that form a complex molecular network known as the
slit diaphragm. It is pivotal for maintaining the size-selective nature of
the glomerular ﬁltration barrier [2].
Nephrotic patients have increased relative risk of cardiovascular in-
farction, resulting in an almost threefold increase in cardiac mortality
[3]. It is a widely held view that impaired endothelial function is the ini-
tial step in atherogenesis,which is largely responsible for ischemic heart
disease and thrombotic strokes occurring decades later [4]. Additionally,endothelial dysfunction has been recognized in adult nephrotic patients
[5]. Moreover, the endothelial dysfunction in these patients was corre-
lated with levels of low-density lipoprotein (LDL) cholesterol, which
improved after statin therapy [6].
Glycocalyx, an approximately 1-μm-thick carbohydrate-rich struc-
ture with antiadhesive and anticoagulant properties that protects the
endothelium and maintains vascular barrier function [7], has never
been studied in nephrotic patients. The roles of glycocalyx include
maintenance of the vascular permeability barrier, mediation of shear-
stress-dependent nitric oxide production, and housing vascular protec-
tive enzymes (for example, superoxide dismutase), as well as housing a
wide array of coagulation inhibition factors, such as antithrombin, the
protein C system, and tissue factor pathway inhibitor [8]. Glycocalyx
also modulates the inﬂammatory response by preventing leukocyte ad-
hesion and by binding to several ligands, including chemokines, cyto-
kines, and growth factor [9, 10].
Although not clearly evaluated, some authors postulate that
glycocalyx injury can be the ﬁrst step in endothelial dysfunction and
Table 1
Clinical and biomarker characteristics of control subjects and patients.
Glomerulopathy
patients
(n = 49)
Controls
(n = 25)
p
Age (years) 39.0 ± 12.1 38.5 ± 9.6 NS
Gender (M/F) 24/25 11/14 NS
Renal biopsy diagnosis
FSGS/ML 23 – –
MN 09 – –
IgAN 06 – –
MPGN 03 – –
Others 08 – –
Serum creatinine (mg/dl) 1.1 ± 0.3 0.82 ± 0.1 b0.001
Serum urea (mg/dl) 62.8 ± 28.0 36.2 ± 11.2 b0.001
GFR (ml/min/1.73 m2) 72.3 ± 13.4 107.4 ± 9.6 b0.001
Serum albumin (g/dl) 2.69 ± 0.86 4.06 ± 0.32 b0.001
Total cholesterol (mg/dl) 286.1 ± 98.4 183.4 ± 26.7 b0.001
LDL-cholesterol (mg/dl) 180.2 ± 80.9 86.0 ± 16.5 b0.001
HDL-cholesterol (mg/dl) 67.3 ± 20.6 50.6 ± 9.5 b0.001
Triglycerides (mg/dl) 254.4 ± 114.2 134.7 ± 27.0 b0.001
24-h urinary protein excretion
(g/1.73 m2)
5.5 ± 2.4 0.09 ± 0.01a b0.001
Flow-mediated dilatation (%) 3.7 ± 1.7 6.6 ± 1.1 b0.001
ICAM-1 (ng/ml) 616.6 ± 219.7 356.9 ± 102.0 b0.001
e-selectin (ng/ml) 129.9 ± 54.2 120.2 ± 61.5 NS
Syndecan-1 (ng/ml) 180.3 ± 64.1 28.2 ± 9.8 b0.001
FSGS: focal and segmental glomerulosclerosis; ML: minimal lesions; MN: membranous
nephropathy; IgAN: IgA nephropathy; MPGN: membranoproliferative glomerulonephritis.
a n = 13 for control group.
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a conserved family of 4 heparan- and chondroitin-sulfate–containing
transmembrane HSPGs (syndecans 1 to 4), being expressed on epitheli-
al cells, endothelial cells, and leukocytes and seems to play a role in tu-
morigenesis [12]. Also, a previous study demonstrated that podocytes
can produce syndecan-1 [13]. Because of its expression in the endothe-
lial and podocyte components of the ﬁltration barrier, syndecan-1 has a
role in nephrotic syndrome, as demonstrated in animal studies [13].
When measured in the blood plasma, syndecan-1 is a biomarker of
endothelial glycocalyx damage, and it is increased in patients with
marked reduction in glomerular ﬁltration rate (GFR), correlating with
markers of endothelial dysfunction [14]. However, its role as a biomark-
er in nephrotic patients is unknown. Additionally, there is no study
evaluatingwhether glycocalyx damage correlates with endothelial dys-
function in nephrotic syndrome.
2. Methods
2.1. Subjects
This is a cross-sectional study performed from January through
August 2014. Adult patients (age N 18 y) with nephrotic syndrome and
renal biopsy indication by the assistant physician were included. Ne-
phrotic syndrome diagnosiswas performedwhen patients had 24-h uri-
nary protein excretion N3.5 g/24 h/1.73 m2, edema, hypoalbuminemia,
and elevated serum lipids. Patients with signiﬁcant reduction in renal
function (glomerular ﬁltration rate b60 ml/min) were not included.
GFR was estimated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation [15].
Subjects with cardiovascular disease, diabetes, hypothyroidism,
liver disease, alcoholism, postural hypotension, concurrent diseases,
and signiﬁcant psychiatric disorders were excluded. Also, patients re-
ceiving statin therapy were excluded. Patients receiving angiotensin-
converting enzyme inhibitors, angiotensin II receptor antagonists,
diuretics, or any other antihypertensive drugs were not excluded, as
these constitute the best clinical practice. All renal biopsies were indi-
cated after consultation with an independent nephrologist.
Because some biomarkers do not have an established normal range,
a control group was included. The control group comprised subjects
with no renal disease or signiﬁcant comorbidity that were recruited
from the community. Subjects were studied while off lipid-lowering
drugs and aspirin.
Blood samples and vascular function studies of the brachial artery
and forearm microcirculation were carried out in the morning after a
12-h fasting from food and beverages and after resting in the supine po-
sition for at least 15 min. Smoking was not allowed on the day of the
test. The Institutional Ethical Committee approved this study, and pa-
tients signed the informed consent term prior to enrollment.
2.2. Flow-mediated dilatation
Flow-mediated dilation (FMD) was assessed in all subjects noninva-
sively by B-mode high-resolution ultrasound imaging (Medison CO
Ltd.) according to current guidelines [16]. Brieﬂy, each patient remained
in a quiet, temperature-controlled room and rested for 20 min before
any measurement was performed. A 7.0-MHz linear array transducer
was used to measure the diameter of the right brachial artery at end-
diastole using electronic calipers. After a baseline measurement, a cuff
ﬁtted distally to the brachial artery was inﬂated, altering arterial ﬂow
for 5 min. The brachial artery was scanned continuously for 60–90 sec
after cuff deﬂation and the vessel's maximal diameter was deﬁned
(diameter during reactive hyperemia). FMD was calculated as the per-
cent of change in the artery's diameter. Intra-observer variability for
brachial diameter measurements for the researcher was 0.05 ±
0.12 mm. At the end of the protocol, images were obtained again4 min after sublingual nitroglycerin (0.4 mg) for measurement of
endothelium-independent dilatation.
2.3. Laboratory measurements
Blood samples were collected into tubes containing ethylenedi-
aminetetraacetic acid (EDTA). These samples were immediately proc-
essed and frozen at −80 °C for later measurement of syndecan-1,
intercellular adhesion molecule-1 (ICAM-1), and e-selectin. Syndecan-
1 was measured as a biomarker of endothelial glycocalyx damage a
using commercially available enzyme-linked immunosorbent assay kit
(Abcam). Intercellular adhesion molecule-1 (ICAM-1), a marker of
endothelial cell activation, was measured using a commercially avail-
able enzyme-linked immunosorbent assay kit (Life Technologies).
Moreover, e-selectin was measured using a commercially available
enzyme-linked immunosorbent assay kit (Abcam).
Moreover, medical records were retrieved to assess laboratory data
at the time of the kidney biopsy and the last evaluation prior to study in-
clusion. Laboratory data included an assessment of serum creatinine,
serum urea, serum albumin, total cholesterol, low-density lipoprotein
cholesterol (LDL), high-density lipoprotein (HDL) cholesterol, triglycer-
ides, and 24-h urinary protein excretion rate.
2.4. Statistical analysis
Descriptive statistics are expressed as mean ± SD or absolute num-
bers as appropriate. All variables were tested for normal distribution
using the Kolmogorov–Smirnov test. Student's t-test was applied to
compare means of continuous variables and normal distribution data
between patients and the control group.
Partial Pearson's correlation coefﬁcients (r) were used to determine
adjusted correlations between the analyzed variables. Subsequent mul-
tiple linear regressionmodeling was used to determinewhich variables
that were signiﬁcant in the univariate analysis were independently as-
sociated with FMD. Two models for FMD were determined separately.
In the second model, we added all endothelial and glycocalyx bio-
markers: ICAM-1, e-selectin, and syndecan-1. Backwards elimination
was performed, and variables (interaction terms and predictors) that
Table 3
Multivariate analysis to determine the association of endothelial/glycocalyx biomarkers and
nephrotic syndrome features with endothelial dysfunction evaluated by ﬂow-mediated
dilatation.
Variable Model 1 Model 2 (including endothelial
and glycocalyx biomarkers)
Standardized
β coefﬁcient
p Standardized
β coefﬁcient
p
Gender (male) 0.183 NS 0.166 NS
Age (years) −0.412 0.031 0.068 NS
GFR (ml/min/1.73 m2) 0.054 NS 0.090 NS
Serum albumin (g/dl) 0.126 NS 0.183 NS
Total cholesterol (mg/dl) −0.317 NS −0.250 NS
LDL-cholesterol (mg/dl) −0.433 0.002 −0.171 NS
HDL-cholesterol (mg/dl) 0.183 NS 0.086 NS
Triglycerides (mg/dl) −0.039 NS −0.130 NS
24-hour urinary protein
excretion (mg/1.73 m2)
−0.393 0.021 −0.289 NS
ICAM-1 (ng/ml) – – −0.151 NS
e-selectin (ng/ml) – – −0.275 NS
Syndecan-1 (ng/ml) – – −0.464 0.009
ICAM-1: intercellular adhesion molecule-1.
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from the model. Stepwise selection was also performed interactively,
where variables with a p b 0.10 were added to the model and variables
with a p N 0.05 were removed. The statistical analysis was performed
using SPSS 19.0 for windows and p b 0.05 was considered statistically
signiﬁcant.
3. Results
3.1. Patients' characteristics
Glomerular histology, glomerular ﬁltration rate, and other nephrotic
syndrome-related variables of the patients are described in Table 1. Of
49 patients with nephrotic syndrome, 25 (51.0%) were females. The
mean age of patients was 39.0 ± 12.1 y. Themean 24-h urinary protein
excretion was in the nephrotic range at 5.5 ± 2.4 g/24 h, and serum al-
bumin was decreased at 2.69 ± 0.86 g/dl. Mean glomerular ﬁltration
rate was 72.3 ± 13.4 ml/min/1.73 m2. Thirty-ﬁve patients were being
treated with ACE inhibitors or an angiotensin II receptor antagonist.
None of the patients had initiated immunosuppressive therapy.
Thirty-two patients had clinically detectable peripheral edema.
3.2. Flow-mediated dilatation and endothelial biomarkers
As expected, ﬂow-mediated dilation was reduced in nephrotic
patients in comparison with controls (3.7 ± 1.7 vs. 6.6 ± 1.1%,
p b 0.001). No difference was observed in nitroglycerin-mediated dila-
tion. Nephrotic patients had higher levels of ICAM-1 (616.6 ± 219.7
vs. 356.9 ± 102.0 ng/ml, p b 0.001) and syndecan-1 (180.3 ± 64.1 vs.
28.2 ± 9.8 ng/ml, p b 0.001). No signiﬁcant difference was observed
regarding e-selectin levels (129.9 ± 54.2 vs. 120.2 ± 61.5 ng/ml,
p = 0.489).
3.3. Association between nephrotic syndrome features and
endothelial markers
After adjusting for age and glomerularﬁltration rate, syndecan-1was
signiﬁcantly associated with 24-h urinary protein excretion, total cho-
lesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides. ICAM-1
was associated only with serum total cholesterol, while e-selectin was
associated with LDL-cholesterol. Flow-mediated dilation was associated
with 24 h-urinary protein excretion, serum total cholesterol, and
LDL-cholesterol. All correlations between biomarkers and nephrotic
syndrome features are shown in Table 2.
3.4. Glycocalyx seems to intermediate nephrotic syndrome damage on
endothelial function
We disclosed a strong and inverse correlation between syndecan-1
and ﬂow-mediated dilation (r = -0.519, p b 0.001). To further evaluate
the association between nephrotic syndrome features, endothelial
glycocalyx injury, and endothelial function,weperformed2 linear regres-
sionmodels, bothwithﬂow-mediated dilation as the dependent variable.Table 2
Partial correlations (adjusted for age and glomerular ﬁltration rate) between endothelial/glyco
Serum albumin Total cholesterol LDL-cholesterol
FMD −0.008
p = NS
−0.289
p = 0.014
−0.306
p = 0.005
Syndecan 0.009
p = NS
0.304
p = 0.006
0.311
p = 0.003
ICAM-1 −0.085
p = NS
−0.328
p = 0.026
0.129
p = NS
e-selectin 0.179
p = NS
−0.292
p = 0.012
−0.283
p = 0.023
FMD: ﬂow-mediated dilatation; ICAM-1: intercellular adhesion molecule-1.In the ﬁrst model, we included gender, age, glomerular ﬁltration
rate, and all nephrotic syndrome features (24-h urinary protein excre-
tion, serum albumin, serum total cholesterol, LDL-cholesterol, HDL-
cholesterol, and triglycerides). The variables independently associated
with ﬂow-mediated dilation were age, LDL-cholesterol, and 24-h uri-
nary protein excretion. In the second model, we added all endothelial
and glycocalyx biomarkers: ICAM-1, e-selectin, and syndecan-1. Inter-
estingly, only syndecan-1 was independently associated with ﬂow-
mediated dilation (Table 3).
4. Discussion
In the present study, we assessed nephrotic patients to evaluate if
there was any glycocalyx damage and if there was an association of gly-
cocalyx damage with endothelial dysfunction in this population. To ex-
clude any bias due to reduced renal function, we selected only patients
with near-normal renal function. We demonstrated for the ﬁrst time
that nephrotic patients have signiﬁcant endothelial glycocalyx damage
as demonstrated by high levels of syndecan-1. Moreover, endothelial
glycocalyx damage is associated with several laboratory features of ne-
phrotic syndrome (24-h urinary protein excretion, LDL-cholesterol,
HDL-cholesterol, and triglycerides) and seems to be a link between ne-
phrotic syndrome and endothelial dysfunction in these patients.
It is already known that nephrotic patients have endothelial
dysfunction demonstrated by a reduction in FMD [5]. Moreover, these
patients also have high levels of endothelial activation biomarkers
[17, 18]. In the ﬁrst part of our study, we conﬁrmed these data in our
population. Nephrotic patients had reduced FMD, characterizing a re-
duced NO production by the endothelium. When nitroglycerin was ad-
ministered, there was no difference in arterial dilatation (endothelium-
independent vasodilatation); demonstrating that only endothelium-
dependent vasodilatation was impaired. Although ICAM-1 level wascalyx biomarkers and nephrotic syndrome features.
HDL-cholesterol Triglycerides 24 h-urinary protein excretion
−0.050
p = NS
0.061
p = NS
0.289
p = 0.002
0.360
p = 0.001
0.285
p = 0.019
0.333
p = 0.002
0.011
p = NS
−0.096
p = NS
0.120
p = NS
−0.020
p = NS
−0.009
p = NS
0.124
p = NS
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ences in relation to e-selectin. This is in accordance with a previous
study, where nephrotic patients had higher levels of ICAM-1 but not
of e-selectin [18]. Our study adds to the body of knowledge on endothe-
lial damage in nephrotic syndrome, demonstrating that not only
endothelial cell are activated, but there is also signiﬁcant glycocalyx en-
dothelial damage.
It has been already demonstrated that syndecan-1 is elevated in pa-
tients with advanced renal impairment [14]. To exclude this bias, we in-
cluded only patients with eGFR N 60 ml/mi/1.73 m2, so it is highly
improbable that this increase in syndecan-1 is secondary to severe im-
pairment. Moreover, all correlations were adjusted for age and renal
function. Even after these adjustments, glycocalyx damage in nephrotic
syndrome was associated with almost all nephrotic syndrome features
(serum lipids fraction levels and 24 h-urinary protein excretion).
The endothelial glycocalyx plays an important role in sensing, trans-
mitting, and transducing extracellular surface ﬂuid mechanical forces
into biological responses at the cell membrane, cytoskeleton, basal
adhesion plaques, and intercellular junctions [7]. The importance of gly-
cocalyx as a mechanosensor and mechanotransmitter in mediating
ﬂow-induced NO release and cell remodeling has been well demon-
strated in vitro and in vivo [19]. A degraded glycocalyx promotes endo-
thelial dysfunction that leads to atherosclerosis—the underlying cause
ofmost heart attacks, strokes, aneurysms, andperipheral vascular disor-
ders [11]. According to this pathophysiology, FMDwas inversely associ-
ated with syndecan-1 levels in our nephrotic patients.
In previous studies, the group of Irish et al. disclosed that
dyslipoproteinemia was probably the main cause of endothelial dys-
function in conduit arteries of patients with nephrotic syndrome, sug-
gesting it is the basis for their increased risk of cardiovascular disease
[5]. In our data, LDL-cholesterol was also independently associated
with FMD after adjusting for several confounders. However, when
syndecan-1 was included in the multivariate model, it remained as the
only variable associated with FMD and LDL-cholesterol was no longer
associated with FMD. After these statistical analyses, the four steps of
Baron and Kenny's procedures [20] were performed, and it can be sug-
gested that syndecan-1, a marker of glycocalyx damage, is a mediator
between dyslipoproteinemia and endothelial dysfunction.
Considered all together, our data allow us to suggest that glycocalyx,
in addition to being a damaged structure in nephrotic syndrome, has an
important role in promoting endothelial dysfunction in these patients.
This information is important, as future interventions aiming to stabilize
glycocalyx structure can reduce atherosclerosis progress in these
patients.
Our study has several limitations. Firstly, because of the cross-
sectional design of the study, we cannot conclude that there is a causal
association between endothelial glycocalyx damage and endothelial
dysfunction. However, the lack of association between FMD and ne-
phrotic syndrome features after adding syndecan-1 levels strongly sup-
ports it. Secondly, we did not follow these patients to verify whether
syndecan-1 levels returned to basal level after nephrotic syndrome
remission.
In conclusion, we demonstrated that syndecan-1, a maker of endo-
thelial glycocalyx damage, is increased in patients with nephroticsyndrome and near-normal renal function. Moreover, we determined
its association with nephrotic syndrome features and suggest it can
have a role in endothelial dysfunction observed in these patients.References
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